Agilent Technologies, Inc.
A
주식 순위
#504
Agilent Technologies, Inc. delivers specialized, application-focused... Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
주가
$169.80
마지막 동기화: 2026-10-19
시가총액
$47.88B
변동 (1일)
-1.75%
변동 (1년)
18.74%
국가
US
거래 Agilent Technologies, Inc. (A)
카테고리
Healthcare
Agilent Technologies, Inc. (A)의 P/E 비율
October 2026 기준 P/E 비율 TTM: 34.18
Agilent Technologies, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 34.18입니다. 2024년 말 기준 P/E 비율은 29.32였습니다.
Agilent Technologies, Inc.의 P/E 비율 기록 (2000 ~ 2026)
매년 말 P/E 비율
| 연도 | P/E 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 34.18 | 7.53% |
| 2025 | 31.79 | 8.43% |
| 2024 | 29.32 | 19.62% |
| 2023 | 24.51 | -25.70% |
| 2022 | 32.99 | -16.40% |
| 2021 | 39.46 | -10.06% |
| 2020 | 43.87 | 97.56% |
| 2019 | 22.21 | -66.26% |
| 2018 | 65.82 | 105.51% |
| 2017 | 32.03 | 3.72% |
| 2016 | 30.88 | -1.53% |
| 2015 | 31.36 | 30.78% |
| 2014 | 23.98 | 40.24% |
| 2013 | 17.10 | 120.07% |
| 2012 | 7.77 | -14.53% |
| 2011 | 9.09 | -27.90% |
| 2010 | 12.61 | -106.38% |
| 2009 | -197.44 | -2,475.14% |
| 2008 | 8.31 | -48.91% |
| 2007 | 16.27 | 420.46% |
| 2006 | 3.13 | -95.86% |
| 2005 | 75.57 | 246.76% |
| 2004 | 21.79 | -664.77% |
| 2003 | -3.86 | -7.51% |
| 2002 | -4.17 | -110.20% |
| 2001 | 40.89 | 120.97% |
| 2000 | 18.51 | 0.00% |
유사 기업 또는 경쟁사의 P/E 비율
| 회사 | P/E 비율 | P/E 비율 차이 | 국가 |
|---|---|---|---|
| 36.15 | 5.76% |
US
|
|
| 39.77 | 16.35% |
US
|
|
| -290.26 | -949.09% |
US
|
|
| - | - |
CN
|
|
| 37.15 | 8.67% |
US
|
P/E 비율 읽는 방법
P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.
P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.
양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.